Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats (Am J Physiol Endocrinol Metab. (2011), 301, (E853?E863),10.1152/ajpendo.00048.2011);Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 301, Issue 5, 2011, Pages 388-

  Chen, Kuan Hsing ^a,c   Cheng, Mei Ling ^a   Jing, Yu Hong ^b   Chiu, Dniel Tsun Yee ^a   Shiao, Ming Shi ^a   Chen, Jan Kan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b LANZHOU UNIVERSITY   (China)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

AMP activated kinase; Carnitine; Diabetes; Metabolomics

Indexed keywords

ACETYLCARNITINE; BRANCHED CHAIN AMINO ACID; CARNITINE; CARNITINE DERIVATIVE; GLUCOSE; HISTIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MUSCLE PROTEIN; RESVERATROL; SIRTUIN 1;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOGENESIS; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; ELECTROSPRAY MASS SPECTROMETRY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; INSULIN DEFICIENCY; LIVER MITOCHONDRION; MALE; METABOLIC DISORDER; METABOLOME; MUSCLE ATROPHY; MUSCLE MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TANDEM MASS SPECTROMETRY; URINE LEVEL;

EID: 80054895077     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.zh1-6453-corr.2011     Document Type: Erratum

References (49)

1. Adams SH, Hoppel CL, Lok KH, Zhao L, Wong SW, Minkler PE, Hwang DH, Newman JW, Garvey WT. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 139: 1073-1081, 2009.
2. Bain JR, Stevens RD, Wenner BR, Ilkayeva O, Muoio DM, Newgard CB. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58: 2429-2443, 2009.
3. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337-342, 2006.
4. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
5. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M, Bertelli A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 17: 1-3, 1995.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
7. Busquets S, Fuster G, Ametller E, Olivan M, Figueras M, Costelli P, Carbo N, Argiles JM, Lopez-Soriano FJ. Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clin Nutr 26: 239-244, 2007.
8. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ, Shoelson SE. IKK/NF-B activation causes severe muscle wasting in mice. Cell 119: 285-298, 2004.
9. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a ''causal'' antioxidant therapy. Diabetes Care 26: 1589-1596, 2003.
10. Charlton M, Nair KS. Protein metabolism in insulin-dependent diabetes mellitus. J Nutr 128: 323S-327S, 1998.
11. Griffin JL. Metabolic profiles to define the genome: can we hear the phenotypes? Philos Trans R Soc Lond B Biol Sci 359: 857-871,2004.
12. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-885, 2007.
13. Hasselbaink DM, Glatz JF, Luiken JJ, Roemen TH, Van der Vusse GJ. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J 371: 753-760, 2003.
14. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, Zang M. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283: 20015-20026, 2008.
15. Hung LM, Su MJ, Chen JK. Resveratrol protects myocardial ischemiareperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic Biol Med 36: 774-781, 2004.
16. Hunter RB, Kandarian SC. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114: 1504-1511, 2004.
17. Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal 49: 976-982, 2009.
18. Jing YH, Chen KH, Yang SH, Kuo PC, Chen JK. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab Res Rev 26: 212-222, 2010.
19. Karastergiou K, Kaski JC. Medical management of the diabetic patient with coronary artery disease. Curr Pharm Des 14: 2527-2536, 2008.
20. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122, 2006.
21. Louard RJ, Fryburg DA, Gelfand RA, Barrett EJ. Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle. J Clin Invest 90: 2348-2354, 1992.
22. Mamoulakis D, Galanakis E, Dionyssopoulou E, Evangeliou A, Sbyrakis S. Carnitine deficiency in children and adolescents with type 1 diabetes. J Diabetes Complications 18: 271-274, 2004.
23. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519, 2000.
24. Maritim AC, Sanders RA, Watkins JB, 3rd. Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-induced diabetic rats. J Nutr Biochem 14: 288-294, 2003.
25. Mourkioti F, Kratsios P, Luedde T, Song YH, Delafontaine P, Adami R, Parente V, Bottinelli R, Pasparakis M, Rosenthal N. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 116: 2945-2954, 2006.
26. Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. J Clin Invest 95: 2926-2937, 1995.
27. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421, 2002.
28. Nguyen TT, Wong TY. Retinal vascular changes and diabetic retinopathy. Curr Diab Rep 9: 277-283, 2009.
29. Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, Stevens RD, Hegardt FG, Muoio DM. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 284: 22840-22852, 2009.
30. Owen OE, Markus H, Sarshik S, Mozzoli M. Relationship between plasma and muscle concentrations of ketone bodies and free fatty acids in fed, starved and alloxan-diabetic states. Biochem J 134: 499-506, 1973.
31. Palsamy P, Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin- nicotinamide-induced diabetic rats. Chem Biol Interact 179: 356-362, 2009.
32. Ragazzi E, Froldi G, Fassina G. Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. Pharmacol Res Commun 20 Suppl 5: 79-82, 1988.
33. Rolinski B, Arnecke R, Dame T, Kreischer J, Olgemoller B, Wolf E, Balling R, Hrabe de Angelis M, Roscher AA. The biochemical metabolite screen in the Munich ENU Mouse Mutagenesis Project: determination of amino acids and acylcarnitines by tandem mass spectrometry. Mamm Genome 11: 547-51, 2000.
34. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212: 167-178, 2006.
35. Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G, Evangelista V, Cerletti C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 123: 1691-1699, 1998.
36. Russell ST, Wyke SM, Tisdale MJ. Mechanism of induction of muscle protein degradation by angiotensin II. Cell Signal 18: 1087-1096, 2006.
37. Smith JJ, Kenney RD, Gagne DJ, Frushour BP, Ladd W, Galonek HL, Israelian K, Song J, Razvadauskaite G, Lynch AV, Carney DP, Johnson RJ, Lavu S, Iffland A, Elliott PJ, Lambert PD, Elliston KO, Jirousek MR, Milne JC, Boss O. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol 3: 31, 2009.
38. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 290: E1339-E1346, 2006.
39. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, Chung JH. AMPK-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563 2010.
40. Vigili de Kreutzenberg S, Tiengo A, Avogaro A. Cerebrovascular disease in diabetes mellitus: the role of carotid intima-media thickness. Nutr Metab Cardiovasc Dis 19: 667-673, 2009.
41. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nat Med 17: 448-453, 2011.
42. Weckwerth W. Metabolomics in systems biology. Annu Rev Plant Biol 54: 669-689, 2003.
43. Winter SC, Simon M, Zorn EM, Szabo-Aczel S, Vance WH, O'Hara T, Higashi L. Relative carnitine insufficiency in children with type I diabetes mellitus. Am J Dis Child 143: 1337-1339, 1989.
44. Wishart, DS. Metabolomics in humans, and other mammals. In: Metabolomics: Quantitative and Qualitative Analysis of Metabolites, edited by Villas-Boas S. New York: John Wiley & Sons, 2007, p. 253-287.
45. Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation. Br J Cancer 91: 1742-1750, 2004.
46. Wyke SM, Tisdale MJ. Induction of protein degradation in skeletal muscle by a phorbol ester involves upregulation of the ubiquitin-proteasome proteolytic pathway. Life Sci 78: 2898-2910, 2006.
47. Yechoor VK, Patti ME, Saccone R, Kahn CR. Coordinated patterns of gene expression for substrate and energy metabolism in skeletal muscle of diabetic mice. Proc Natl Acad Sci USA 99: 10587-10592, 2002.
48. 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal Biochem 383: 76-84, 2008.
49. 1H-NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. Am J Physiol Renal Physiol 300: F947-F956, 2011.